Christopher Stone, our CEO, General Counsel and Secretary, joined the Company in February 2009 as VP, General Counsel and Secretary and assumed the role of CEO on May 15, 2021. He brings more than 30 years of legal experience. Before joining PDL, Mr. Stone served as Vice President of Legal Affairs and Corporate Secretary at LS9, an advanced biofuels development company, where his work included a focus on intellectual property protection, research collaborations and licensing.
Prior to that, Mr. Stone was Vice President of Intellectual Assets USA at Danisco A/S, a global producer of food ingredients, enzymes and bio-based solutions. From 1994 to 2005, Mr. Stone was with Genencor International, a biotechnology company acquired by Danisco in 2005, most recently as Vice President of Intellectual Property and General Patent Counsel. At Genencor, he handled all intellectual property matters, including developing and implementing an overall strategy for its domestic and international patent estate of approximately 3,700 patents and patent applications and intellectual property transactions including licensing and research collaboration management, and managed multiple litigation and interference proceedings and numerous European patent oppositions.
Mr. Stone received a J.D. from the National Law Center at George Washington University and a B.S. in Biochemistry from the University of Massachusetts. He is an active member of the District of Columbia Bar, Nevada Bar and California Bar, and was admitted to practice before the United States Patent & Trademark Office in 1992.
Christy Horgan
Chief Financial Officer
Christy Horgan, our Chief Financial Officer, joined the Company in January 2017. Ms. Horgan brings to PDL 20 years of accounting and financial reporting experience. Before joining PDL, Ms. Horgan was a principal at Excelsis Accounting Group in Reno, NV. While at Excelsis (2005 to 2016), Ms. Horgan was responsible for audit and other attestation services for both public and private companies. She also provided consulting services requiring expertise with financial statement preparation and analysis, internal controls, business planning and risk assessment.
Ms. Horgan began her career in public accounting at Deloitte and provided audit and related financial services to public and private companies. Ms. Horgan holds a bachelor’s degree and master’s degree in accounting from the University of Washington. She is a licensed Certified Public Accountant.
Board of Directors
Elizabeth O’Farrell
Chairperson
Ms. O’Farrell joined the PDL BioPharma Board of Directors in June 2018. Ms. O’Farrell previously served 24 years with Eli Lilly and Company, most recently as Chief Procurement Officer from 2012 to 2017.
At Eli Lilly, Ms. O’Farrell advanced through various executive management positions, including Senior Vice President, Policy and Finance; Senior Vice President, Finance; Chief Financial Officer, Lilly USA; Chief Financial Officer, Lilly Canada; and General Auditor. Before joining Eli Lilly, Ms. O’Farrell was an accountant with Boise Cascade Office Products and auditor at Whipple & Company and Price Waterhouse. Ms. O’Farrell holds a B.S. in accounting with honors and an MBA in management information systems, both from Indiana University.
Ms. O’Farrell currently serves on the Board of Directors of Geron Corporation and served as a Board member of the YMCA of Greater Indianapolis for more than a decade and as its Chair from 2014 to 2016. She is a member of the Finance Committee of the United Way of Brevard in Brevard County, FL., and previously served on the Boards of the Washington Township Schools Foundation and Keep Indianapolis Beautiful.
Ms. O’Farrell brings to the PDL Board of Directors extensive experience as a senior executive of a major pharmaceutical company with global operations. She is the chairperson of the PDL BioPharma Board of Directors.
Dominique Monnet
Mr. Monnet joined the PDL BioPharma Board of Directors in December 2018. He serves as President and Chief Executive Officer of PDL BioPharma. He joined the Company in 2017 as President and assumed the dual role of President and Chief Executive Officer in 2018. Before joining PDL, Mr. Monnet served as senior vice president and chief marketing officer of Alexion Pharmaceuticals from 2014 to 2015, where he was responsible for commercial operations in the U.S. and Latin America and oversaw new products and global business operations functions.
From 2002 to 2013, he was a senior executive at Amgen Inc., where he served in a number of key commercial leadership positions in the U.S. and internationally. As vice president and general manager for Amgen’s Inflammation Business Unit in 2011 to 2013, he was responsible for accelerating the growth of the Enbrel® franchise in the highly competitive U.S. market. Prior to this, he served as vice president and head of Amgen’s Global Marketing and Commercial Development, where he led the marketing strategies and global launches of new products across a range of therapeutic areas.
From 2002 through 2006, Mr. Monnet was based in Zug, Switzerland, where he served as Amgen’s Vice President of International Marketing and Business Operations, building Amgen’s international commercial capability and leading the creation of its successful international franchises in oncology and nephrology. Before joining Amgen, Mr. Monnet held positions of increasing responsibility in line commercial management and global marketing over 19 years at Schering-Plough – including General Manager of its affiliate in the UK and Republic of Ireland — Ciba-Geigy and Alza Corporation. Mr. Monnet holds a business degree from EDHEC Business School in Lille, France, and an MBA from INSEAD in Fontainebleau, France.
Mr. Monnet brings the Board of Directors of PDL BioPharma a strong understanding of the pharmaceutical and biotechnology industries and experience in the commercialization of pharmaceutical products.
Christopher Stone
Mr. Stone joined the PDL BioPharma Board of Directors in May, 2021. He serves as the CEO, General Counsel and Secretary, joined the Company in February 2009 as VP, General Counsel and Secretary and assumed the role of CEO on May 15, 2021. He brings more than 30 years of legal experience. Before joining PDL, Mr. Stone served as Vice President of Legal Affairs and Corporate Secretary at LS9, an advanced biofuels development company, where his work included a focus on intellectual property protection, research collaborations and licensing.
Prior to that, Mr. Stone was Vice President of Intellectual Assets USA at Danisco A/S, a global producer of food ingredients, enzymes and bio-based solutions. From 1994 to 2005, Mr. Stone was with Genencor International, a biotechnology company acquired by Danisco in 2005, most recently as Vice President of Intellectual Property and General Patent Counsel. At Genencor, he handled all intellectual property matters, including developing and implementing an overall strategy for its domestic and international patent estate of approximately 3,700 patents and patent applications and intellectual property transactions including licensing and research collaboration management, and managed multiple litigation and interference proceedings and numerous European patent oppositions.
Mr. Stone received a J.D. from the National Law Center at George Washington University and a B.S. in Biochemistry from the University of Massachusetts. He is an active member of the District of Columbia Bar, Nevada Bar and California Bar, and was admitted to practice before the United States Patent & Trademark Office in 1992.
